Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 311 followers
Latest posts
Last updated 2 days ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
2 days ago
Group sales were up by 5%1 at constant exchange rates (CER) (stable...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
9 days ago
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as...
Reminder: Invitation to Roche’s Half Year Results 2024 Presentation
9 days ago
Roche will publish its Half Year Results of 2024 prior to the...
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
9 days ago
More than 90% of patients had absence of DME after four years...
Reminder: Invitation to Roche’s Virtual Ophthalmology Update IR Event
10 days ago
We are pleased to invite investors and analysts to participate in our...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
10 days ago
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of...
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
18 days ago
The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose...
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
18 days ago
The FDA has approved updates to Susvimo, which will be available to...
FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
22 days ago
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
23 days ago
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary...
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
29 days ago
Positive recommendation is based on two Phase III studies. In addition to...
CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
29 days ago
If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for...